» Articles » PMID: 22279417

The Two Faces of Janus Kinases and Their Respective STATs in Mammary Gland Development and Cancer

Overview
Journal J Carcinog
Publisher Biomed Central
Date 2012 Jan 27
PMID 22279417
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Since its discovery as "just another kinase" more than twenty years ago, the family of JAK tyrosine kinases and their respective Signal Transducers and Activators of Transcription (STATs) has been a center of attention in the areas of signal transduction, development, and cancer. The subsequent designation of JAKs as Janus kinases after the mythical two-faced Roman God of the doorways accurately portrays the analogous and sometimes contrasting molecular and biological characteristics of these tyrosine kinases. The two "faces" of JAKs are their structurally similar kinase and pseudo-kinase domains. As essential parts of various transmembrane receptor complexes, these tyrosine kinases function at cellular gateways and relay signals from growth factors to their respective intracellular targets. The multifaceted nature of JAKs becomes evident from their ability to activate specific STATs during distinct phases of normal mammary gland development. Studies in breast cancer cells and genetically engineered mouse models also show that JAK/STAT signaling possesses a "two-faced" role during breast cancer initiation and progression. This review will highlight recent findings about important biological functions of JAKs and STATs during normal mammogenesis, with particular emphasis on the Jak2/Stat5 pathway as well as Jak1/2/Stat3 signaling complexes. In addition, we will discuss how the importance of these signaling networks changes during carcinogenesis. With JAK inhibitors currently under development to treat myeloproliferative disorders, determining the essential functions of JAKs at particular stages of disease initiation and progression is of critical importance to predict the efficacy of these agents for targeted therapies against breast cancer.

Citing Articles

Integrated Transcriptomic Analyses of Liver and Mammary Gland Tissues Reveals the Regulatory Mechanism Underlying Dairy Goats at Late Lactation When Feeding Rumen-Protected Lysine.

Dai W, Han B, Sun Y, Hou P, Wang C, Li W Int J Mol Sci. 2024; 25(21).

PMID: 39518929 PMC: 11546963. DOI: 10.3390/ijms252111376.


Update on the role of copanlisib in hematologic malignancies.

Le T, Jerel D, Bryan L Ther Adv Hematol. 2021; 12:20406207211006027.

PMID: 33889376 PMC: 8040547. DOI: 10.1177/20406207211006027.


Long noncoding RNA promotes retinoblastoma progression by acting as a competing endogenous RNA for microRNA-769-5p, thereby increasing STAT3 expression.

Dong Y, Wan G, Yan P, Qian C, Li F, Peng G Aging (Albany NY). 2020; 12(9):7729-7746.

PMID: 32369777 PMC: 7244063. DOI: 10.18632/aging.103075.


Long noncoding RNA SNHG14 promotes the aggressiveness of retinoblastoma by sponging microRNA‑124 and thereby upregulating STAT3.

Sun X, Shen H, Liu S, Gao J, Zhang S Int J Mol Med. 2020; 45(6):1685-1696.

PMID: 32236565 PMC: 7169960. DOI: 10.3892/ijmm.2020.4547.


The association between high mobility group box 1 chromatin protein and mitotic chromosomes in glioma cells.

Jia L, Song H, Fan W, Song Y, Wang G, Li X Oncol Lett. 2020; 19(1):745-752.

PMID: 31897190 PMC: 6924194. DOI: 10.3892/ol.2019.11170.


References
1.
Ormandy C, Camus A, Barra J, Damotte D, Lucas B, Buteau H . Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev. 1997; 11(2):167-78. DOI: 10.1101/gad.11.2.167. View

2.
Parganas E, Wang D, Stravopodis D, Topham D, Marine J, Teglund S . Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998; 93(3):385-95. DOI: 10.1016/s0092-8674(00)81167-8. View

3.
Kisseleva T, Bhattacharya S, Braunstein J, Schindler C . Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002; 285(1-2):1-24. DOI: 10.1016/s0378-1119(02)00398-0. View

4.
Rose-Hellekant T, Arendt L, Schroeder M, Gilchrist K, Sandgren E, Schuler L . Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene. 2003; 22(30):4664-74. PMC: 1630768. DOI: 10.1038/sj.onc.1206619. View

5.
Li G, Robinson G, Lesche R, Martinez-Diaz H, Jiang Z, Rozengurt N . Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development. 2002; 129(17):4159-70. DOI: 10.1242/dev.129.17.4159. View